NRC Form 374A (5-84) U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 20-05766-02
Docket or Reference number: 030-01879
Amendment No. 37

Lahey Clinic Foundation
41 Mall Road
Burlington Massachusetts 01805

"OFFICIAL RECORD COPY"

In accordance with letter dated April 24, 1985, application dated May 1, 1985 and letter dated July 25, 1985, License Number 20-05766-02 is amended as follows:

Items 6., 7., 8. and 9. are amended to read:

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 9.A.
B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. 2 curies of each byproduct material authorized in Subitem 6.B.
C. Iodine 131	C. Any iodide that has been manufactured, labeled, packaged and distributed in accordance with a specific license issued pursuant to Section 32.72 of 10 CFR Part 32 or a specific license issued to the manufacturer by an Agreement State pursuant to equivalent State Regulation.	C. As necessary for uses authorized in Subitem 9.C.
D. Any byproduct material listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. Any radiopharmaceutical listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. As necessary for uses authorized in Subitem 9.D.
E. Any byproduct material listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35	E. Any sealed source listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35	E. 2000 millicuries total for sources authorized in Subitem 6.E.
F. Any byproduct material listed in Section 31.11(a) of 10 CFR 31	F. Prepackaged kits	F. 3 millicuries of each byproduct material authorized in Subitem 6.F.

ML18.

(continued)

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
G. Xenon 133	G. Gas or gas in solution that is the subject of an active (i.e., not withdrawn or terminated) "New Drug Application" (NDA) approved by FDA or an active (i.e., not withdrawn, terminated or on "clinical hold") "Notice of Claimed Investigational Exemption for a New Drug" (IND) that has been accepted by FDA	G. 400 millicuries
H. Uranium (Depleted in Uranium 235	H. Encapsulated in copper tube and chrome plated	H. 10 kilograms
I. Strontium 90	I. Sealed source (Tracer RA-1A)	I. 27 millicuries
J. Strontium 90	J. Sealed source (Nuclear Enterprises Model 2503/3)	J. 10 millicuries
K. Nickel 63	K. Sealed source	K. 11 millcuries
L. Hydrogen 3	L. Any	L. 10 millicuries
M. Carbon 14	M. Any	M. 10 millicuries
N. Iodine 129	N. Sealed sources	N. 0.2 microcuries
O. Americium 241	O. Sealed sources	O. 6 microcuries
P. Cesium 137	P. Sealed sources	P. 201 millicuries
Q. Chromium 51	Q. Any	Q. 2 millicuries
R. Iodine 125	R. Sodium iodide	R. 20 millicuries

9. Authorized use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100 Title 10, Code of Federal Regulations.
B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
C. Any therapeutic procedure listed in Group IV of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
D. Any therapeutic procedure listed in Group V of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
E. Any procedure listed in Group VI of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
F. In vitro studies.
G. Blood flow and pulmonary function studies.
H. As X-ray beam absorber.
I. Treatment of superficial eye disease
J. and K. Standards for instrument calibration
L. through Q. In vitro studies. Instrument calibration.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 20-05766-02
Docket or Reference number: 030-01879
Amendment No. 37

(9. continued)

R. In vitro studies.

Conditions 12. and 19. are amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

Sanford R. Kurtz, M.D.	In vitro studies
Theodore Lo, M.D.	Group VI
Ferdinand A. Salzman, M.D.	Group VI
Francis Scholz, M.D.	Groups I, II and III In vitro studies Xenon-133
Peter Winter, M.D.	Groups I, II and III Iodine 131 as iodide for treatment of hyperthyroidism, cardiac dysfunction, and thyroid carcinoma Xenon-133
Robert E. Wise, M.D.	Groups I, II and III In vitro studies Xenon-133
Marvin Wool, M.D.	Iodine 131 as iodide for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma
Robert S. Wenstrup, Ph.D.	In vitro studies Depleted uranium Strontium 90 and Nickel 63 for instrument calibration
Kenneth Wright, M.S.	In vitro studies Depleted uranium Strontium 90 and Nickel 63 for instrument calibration
William Curby, M.S.	In vitro studies Iodine 129, Americium 241, and Cesium 137 for instrument calibration
Mitchell A. Swartz, M.D.	Group VI
Patricia Leasure	Iodine 125 as iodide for In vitro studies

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 20-05766-02
Docket or Reference number: 030-01879
Amendment No. 37

(continued)

9. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated July 15, 1980; letter dated May 8, 1981, containing ALARA Program; letters dated February 15, 1984, March 19, 1984, June 5, 1984, February 13, 1985 and April 24, 1985; application dated May 1, 1985 and letter dated July 25, 1985. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

For the U.S. Nuclear Regulatory Commission

Original Signed By:
John E. Glenn

Date AUG 30 1985

By _____
Nuclear Materials Safety and
Safeguards Branch, Region I
King of Prussia, Pennsylvania 19406